Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SJP-0135 Phase 3 in Primary Open Angle Glaucoma or Ocular Hypertension
jRCT2031230312Phase 3Completed
- Sponsor
- Senju Pharmaceutical Co., Ltd.
- Start
- Sep 2023
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of brimonidine tartrate + brinzolamide in open-angle glaucoma (OAG) and ocular hypertension (2 arms), sponsored by Senju Pharmaceutical Co., Ltd. Primary endpoint: Intraocular pressure–lowering efficacy of SJP-0135 versus active control. Started Sep 2023; status: completed.
02
Drugs
brimonidine tartrate + brinzolamide
03
Conditions
open-angle glaucoma (OAG)ocular hypertension
Beyond the preview
Go deeper on jRCT2031230312.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031230312.